Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands

PURPOSE: In June 2013 a European Medicines Agency referral procedure concluded that diclofenac was associated with an elevated risk of acute cardiovascular events and contraindications, warnings, and changes to the product information were implemented across the European Union. This study measured t...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales, Daniel R., Morant, Steve V., MacDonald, Thomas M., Mackenzie, Isla S., Doney, Alexander S. F., Mitchell, Lyn, Bennie, Marion, Robertson, Chris, Hallas, Jesper, Pottegard, Anton, Ernst, Martin Thomsen, Wei, Li, Nicholson, Lizzie, Morris, Carole, Herings, Ron M. C., Overbeek, Jetty A., Smits, Elisabeth, Flynn, Robert W. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079064/
https://www.ncbi.nlm.nih.gov/pubmed/31899936
http://dx.doi.org/10.1002/pds.4955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079064/
https://www.ncbi.nlm.nih.gov/pubmed/31899936
http://dx.doi.org/10.1002/pds.4955

Ejemplares similares